About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects.
Quality Assessment
Delcath Systems, Inc. is a high-quality healthcare company with a Compass Score of 88. Profitability, cash flow, and price stability all score well here. The kind of stock long-term investors tend to hold for quality.
Score Breakdown
The Compass Score is based on 6 quality factors identified by academic research.
Click any factor to see detailed metrics
Valuation Metrics
Click any metric for details
Wall Street View
Catalyst Signal
PlusRecent earnings beats and analyst-upgrade momentum. How it works
Analyst Track Record
Financial Health
PlusClick any metric for details
Growth Projections
PlusTechnical Overview
Click any metric for details
Similar High-Quality Stocks
Important Disclaimer
The Compass Score is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always do your own research and consider consulting a financial advisor before making investment decisions.
Unlock Detailed Metrics
Upgrade to Plus to see the actual financial values behind each quality factor.
- See exact ROA, cash flow ratios, and more
- Unlimited stock views + smart search
- Export data to CSV
- Golden Stocks + analyst coverage
Cancel anytime